Summary of Key Points from Conference Call Records Industry Overview - The reports primarily focus on the Hong Kong market and specific sectors such as materials, healthcare, AI, and telecommunications [1][2][4]. Market Performance - The Hang Seng Index increased by 1.5%, the Hang Seng China Enterprises Index rose by 1.2%, and the Hang Seng Technology Index went up by 1.0%, with a total trading volume of HKD 13.6 billion [1]. - Southbound funds recorded a net inflow of USD 164 million, indicating positive investor sentiment despite lower nominal amounts [1]. - The materials sector led the market with a 2.8% increase, followed by the financial sector at 2.3% and healthcare at 1.9% [1]. Sector Analysis Materials Sector - The materials sector saw a rise due to technical support from base metals following a market rebound [2]. - Notable stock movements included: - Innovent Biologics increased by 5.6% after announcing a strategic partnership with Eli Lilly, valued at USD 8.5 billion, marking their largest collaboration to date [2]. - Pop Mart International rose by 5.1%, with its founder reporting over 10 million units sold of the Labubu product last year [2]. AI Sector - The AI sector performed exceptionally well, with the Goldman Sachs China AI Index up by 5.5% and the AI-generated content index up by 4.9% [2]. Telecommunications Sector - Telecommunications stocks lagged, with China Telecom down by 2.4% due to unmet targets and China Mobile down by 1.6% following a downgrade from brokers [4]. Trading Trends - Overall market sentiment showed a shift towards defensive sectors and "safe haven" assets as investors prepared for the upcoming Chinese New Year holiday [2]. - There was a mixed trading approach in consumer stocks, with purchases in apparel and sales in toy and education technology stocks [2]. Individual Stock Performance - Kuaishou's stock fell by 4.3% due to regulatory penalties amounting to CNY 119.1 million for failing to control illegal content dissemination [3]. - Short interest in Kuaishou increased to 7.1% of its float, indicating growing bearish sentiment [3]. Conclusion - The Hong Kong market displayed resilience with significant sector performances, particularly in materials and AI, while telecommunications and certain consumer sectors faced challenges. The upcoming holiday period is influencing trading strategies, with a cautious approach observed among investors [1][2][4].

Core Viewpoint - The Hong Kong stock market showed strong performance in the early session, particularly in the innovative drug sector, indicating a robust demand for pharmaceuticals and a shift towards an "innovation-driven" revenue era in the industry [1] Group 1: Market Performance - Innovative drug stocks performed well, with notable gains: Zai Lab rose over 6%, CanSino Biologics-B increased over 5%, and Rongchang Biologics climbed over 4% [1] - The Hong Kong Innovative Drug ETF (159567) rose over 2%, reflecting the positive sentiment in the sector [1] Group 2: Industry Insights - Analysts attribute the pharmaceutical industry's ability to reach new highs despite ongoing challenges to the continuous demand for medical solutions and the increasing number of unmet needs [1] - Pharmaceutical companies are significantly increasing their R&D investments to address these unmet needs, positioning China as a key player in global innovative drug development [1] - The trend of overseas licensing has been rising year after year, further emphasizing the industry's shift towards innovation [1] Group 3: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the National Index of Hong Kong Innovative Drugs, aiming to reflect the performance characteristics of listed companies in the innovative drug sector [1] - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]

Core Viewpoint - Crystal Tech Holdings (02228) has successfully delivered an automated workstation for formula stability testing to BASF, enhancing BASF's automation system across various high-value fields such as new drug development and chemical synthesis [1] Group 1: Company Developments - Crystal Tech Holdings' stock rose over 4%, reaching 11.8 HKD with a trading volume of 296 million HKD [1] - The automated workstation delivered to BASF supports a comprehensive automation system for sample management, testing analysis, and data management [1] Group 2: Strategic Partnerships - On February 5, Crystal Tech Holdings announced a project agreement and long-term strategic cooperation with Weisheng Pharmaceutical (02561) [1] - The collaboration aims to integrate Crystal Tech's AI and robotics drug development platform with Weisheng's expertise in the endocrine field, focusing on high clinical value indications and innovative targets [1] - This partnership seeks to advance the early discovery and clinical translation of innovative therapies in the endocrine treatment sector, targeting a market potential worth hundreds of billions [1]

【同源康医药】十倍潜力，TY9591新药申请获受理 事件：2月6日， 国家药品监督管理局药品审评中心数据显示，公司甲磺酸艾多替尼片(TY9591)申请已获受理，受 理号为CXHS2600026。 EGFR突变在NSCLC亚裔患者中占比达50%，且#携带EGFR突变患者3年累积脑转移发生率64%，显著高于其他亚 型。 国内2024年三代EGFR市场约180亿元（三代EGFR基本 【同源康医药】十倍潜力，TY9591新药申请获受理 事件：2月6日， 国家药品监督管理局药品审评中心数据显示，公司甲磺酸艾多替尼片(TY9591)申请已获受理，受 理号为CXHS2600026。 EGFR突变在NSCLC亚裔患者中占比达50%，且#携带EGFR突变患者3年累积脑转移发生率64%，显著高于其他亚 型。 国内2024年三代EGFR市场约180亿元（三代EGFR基本已取代一代、二代产品市场），且市场扔持续增长。 #三代EGFR尚无针对脑转移药物获批。 TY9591关键Ⅱ期试验#头对头击败奥希替尼。 同源康医药TY-9591击败奥希替尼，已经预定了百亿单品的市场地位。 此前TY9591纳入CDE优先审评名单，NDA受理后有望于2 ...

Market Overview - The Hang Seng Index is expected to hold at 26,000 points, with the U.S. Federal Reserve's hawkish stance influencing market dynamics and leading to a rebound in the U.S. dollar index [2] - The Chinese government is anticipated to focus on expanding domestic demand and technological self-sufficiency in 2026, with GDP growth targets expected to be set between 4.5% and 5% [2] - Regulatory measures are being implemented to cool the market, including increased financing margin ratios and a reduction in leverage across major exchanges [2] Company News - Alphabet plans to issue high-rated U.S. bonds to raise approximately $15 billion, continuing the trend of significant debt issuance among companies investing heavily in AI infrastructure [4][10] - Alibaba's Gaode Dache has been summoned by the Ministry of Transport due to issues related to price management and operational oversight [4][10] - BYD has filed a lawsuit against the U.S. government seeking the return of all tariffs imposed [4] - Hong Kong Telecom reported a 4% increase in profit for the previous year, with a dividend of 47.97 cents [4] Sector Focus - The travel sector is expected to see strong demand as the Lunar New Year approaches, with an estimated 2,200 inbound tours from mainland China to Hong Kong, involving around 86,000 visitors [9] - The semiconductor industry is projected to experience significant growth driven by strong demand for AI technologies [7] - The logistics sector in China reported a total logistics volume of 368.2 trillion yuan for 2025, reflecting a year-on-year growth of 5.1% [8] Economic Indicators - The U.S. Federal Reserve maintained interest rates in January, indicating a cautious approach to future adjustments based on economic data [5] - The international oil market is expected to face upward pressure on prices due to geopolitical factors, despite an oversupply situation [5] - The Chinese central bank is expected to inject liquidity into the market ahead of the Lunar New Year, with estimates suggesting a liquidity gap of over 3 trillion yuan [8]

消息面上，2月10日，英矽智能与康哲药业宣布在中枢神经系统及自身免疫疾病领域的多个项目上达成 一系列由AI赋能的创新药物研发合作。根据合作协议，双方将结合英矽智能已验证的AI平台与AI赋能 创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，共同推进不少于2个研 发项目的合作开发。同时，英矽智能有望就每个项目获得最高达数千万港元的研发费用支持。 大摩此前研报指出，英矽智能是AIDD领域的领先者，在技术验证与应用方面均取得实质性进展。其化 学模型的执行力支撑其可重复的"1-to-N"创新创造引擎；随着生物学模型的人体验证逐步显现，其潜在 上行弹性有望在整个行业进入广泛AIDD采用期时得到进一步释放。 英矽智能(03696)再涨超7%，高见72.55港元创新高。截至发稿，涨7.22%，报72港元，成交额1448.27万 港元。 ...

Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 7%, reaching a new high of 72.55 HKD, driven by a collaboration announcement with Kanghong Pharmaceutical in AI-enabled drug development for central nervous system and autoimmune diseases [1] Group 1: Company Developments - Insilico Medicine and Kanghong Pharmaceutical have entered into a series of collaborative projects focused on AI-driven innovative drug development [1] - The collaboration will leverage Insilico's validated AI platform and drug development capabilities alongside Kanghong's experienced research team and deep understanding of disease areas [1] - Insilico is expected to receive up to tens of millions of HKD in research funding for each project [1] Group 2: Industry Insights - Morgan Stanley's previous report highlights Insilico Medicine as a leader in the AIDD (AI-Driven Drug Development) field, noting substantial progress in both technology validation and application [1] - The execution capability of Insilico's chemical models supports a repeatable "1-to-N" innovation creation engine, indicating strong potential for scalability [1] - As biological model human validation becomes more evident, the potential upside for Insilico is expected to be further released as the industry enters a broader adoption phase of AIDD [1]

Major Events - Xian Dao Intelligent (00470) has set the offer price for H-shares at HKD 45.80, with the sale volume adjustment rights fully exercised [1] - Lexin Outdoor (02720) has seen a public offering subscription rate of 3654.23 times, with a per share pricing of HKD 12.25 [1] - Aixin Yuan Zhi (00600) has achieved a public offering subscription rate of 104.82 times, with a final offer price of HKD 28.2 per share [1] - Shandong Xinhua Pharmaceutical (00719) has obtained the registration certificate for glucosamine sulfate capsules [1] - United Pharmaceutical (03933) has passed the consistency evaluation for roxithromycin capsules [1] - InnoCare Pharma (03696) has reached several drug development projects in the central nervous system and autoimmune disease fields with Kangzhi Pharmaceutical, valued at tens of millions of HKD [1] - Sunshine Insurance (06963) subsidiary plans to increase capital to Sunshine Asset Management (Hong Kong) for a total of no more than HKD 1 billion [1] - Crystal Tech Holdings (02228) has established a robotics laboratory in BASF, receiving top endorsement from the chemical industry for global technological leadership [1] - Youjia Innovation (02431) has newly secured designated projects in intelligent driving and intelligent cockpit [1] - China Resources Pharmaceutical (03320) is considering the potential sale of approximately 17.87% equity in Tianmai Biotechnology [1] Operating Performance - Hong Kong Telecom-SS (06823) reported a profit attributable to shareholders of HKD 5.286 billion for 2025 [1] - Pop Mart (09992) has achieved global sales of over 400 million units across all IP and product categories in 2025 [1] - Longfor Group (00960) reported a contract sales amount of HKD 2.45 billion in January [1] - China Jinmao (00817) recorded a signed sales amount of HKD 7.603 billion in January, an increase of 13.56% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of 1.7393 million MWh in January, a year-on-year increase of 15.25% [1] - Dekang Agriculture and Animal Husbandry (02419) sold 1.04236 million pigs in January [1] - China Oriental Education (00667) has issued a profit warning, expecting a year-on-year profit increase of 46% to 51% for the 2025 fiscal year [1] - China Nuclear International (02302) has issued a profit warning, expecting gross profit for 2025 to reach no less than approximately HKD 260 million [1] - Mingyuan Cloud (00909) has issued a profit warning, expecting net profit attributable to shareholders for 2025 to be approximately HKD 26.9 million to HKD 32.8 million, turning from loss to profit year-on-year [1]

Group 1 - The core viewpoint of the news is that Xiaofang Pharmaceutical has shown a slight decline in stock price while maintaining a relatively low financing balance compared to its market value, indicating potential investment opportunities [1] - As of February 9, Xiaofang Pharmaceutical's financing balance is 60.80 million yuan, which accounts for 3.69% of its circulating market value, and is below the 10th percentile level over the past year, suggesting a low financing position [1] - The company reported a total revenue of 397 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 8.17%, while the net profit attributable to shareholders increased by 5.09% to 170 million yuan [2] Group 2 - Xiaofang Pharmaceutical has distributed a total of 353 million yuan in dividends since its A-share listing, indicating a commitment to returning value to shareholders [3] - As of September 30, 2025, the number of shareholders has increased to 14,300, with an average of 3,807 circulating shares per person, showing a slight increase in shareholder engagement [2] - Notably, new institutional investors have entered the top ten circulating shareholders list, with GF Multi-Dimensional Emerging Stock holding 753,100 shares, while some previous major shareholders have exited [3]

Group 1 - The company, 泰凌医药 (01011), announced that its shares will be temporarily suspended from trading starting at 9:03 AM on February 10, 2026 [1]